A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Not Recruiting

Trial ID: NCT05271604


This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 in PD-1/L1 failure patients with ROR-2 expression in recurrent or metastatic squamous cell carcinoma of the head and neck.

Official Title

A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Stanford Investigator(s)

A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD

Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)


Inclusion Criteria:

   - Histologically or cytologically confirmed recurrent or metastatic SCCHN Stage III/IV
   and not amenable to local therapy with curative intent (surgery or radiation therapy
   with or without chemotherapy). The eligible primary tumor locations are oropharynx,
   oral cavity, hypopharynx, and larynx. Patients may not have a primary tumor site of
   nasopharynx (any histology).

   - Documented treatment failure of no more than one approved PD-1/L1 inhibitor either
   administered alone or in combination.

Patients must have measurable disease.

   - Age ≥ 18 years

   - Adequate renal function

   - Adequate liver function

   - Adequate hematological function

   - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

   - Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as
   well as known or suspected allergy or intolerance to any agent given during this

   - Patients must not have known human immunodeficiency virus (HIV) infection, active
   hepatitis B and/or hepatitis C.

   - Patients must not be women who are pregnant or breast feeding.


biological: Ozuriftamab Vedotin

biological: PD-1 inhibitor

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elizabeth (Elzbieta) Winters

New Trial Alerts